Drug intelligence / Profile preview

Keluo Xin

Development stage: Unknown
Lead developer: Chengdu Kanghong Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Keluo Xin is an oral Traditional Chinese Medicine (TCM) botanical drug developed by Chengdu Kanghong Pharmaceutical for the treatment of nonproliferative diabetic retinopathy (NPDR). It is a multi-component formulation designed to address the microvascular complications of diabetes by improving retinal microcirculation, reducing vascular permeability, and mitigating oxidative stress and inflammation. The drug is currently in Phase 2 clinical development, where it is being evaluated for its efficacy and safety in patients with moderately severe to severe NPDR, with the goal of slowing disease progression and preventing vision loss.

Brand names: Keluo Xin
Other names: KeluoxinKeluoxin Capsule渴络欣

Targets

VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on Keluo Xin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Keluo Xin.

Explore the full profile